July 3, 2018 Source: Reuters 212
Only six months after first receiving approval from Western countries for its all-important cancer drug, Imfinzi, AstraZeneca has received a fast-tracked approval from Japan.
The immunotherapy drug was approved for lung cancer patients with no chance for surgery whose cancer had not yet spread to other parts of the body.
The Japanese Ministry of Health, Labour and Welfare's decision to grant approval for Imfinzi points to the country’s compelling need to access modern medicines after prolonged hesitation of adoption in the country. This is especially notable since approval in the U.S. was only granted in February of this year for stage III lung cancer and is still pending from the European Union.
This is not the only approval AstraZeneca got from Japan. The company along with their partner Merck announced that Lynparza, which was first approved in Japan for ovarian cancer, received the green light for the treatment of breast cancer.By Ddu
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.